Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors

NCT03666143 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT03666143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03666143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Lead sponsor
BeiGene
Phase
Phase 1
Overall status
Completed
Start date
November 1, 2018
Completion date
January 5, 2023
Enrollment
216 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors